WallStreetZenWallStreetZen

NASDAQ: RIGL
Rigel Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Rigel Pharmaceuticals revenue was $157.47M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $55.3M, up 50.1% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, RIGL annual revenue was $116.9M, with -2.8% growth year-over-year.

RIGL past revenue growth

How has RIGL's revenue growth performed historically?

Company
18.97%
Industry
1,126.32%
Market
34.28%
RIGL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RIGL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RIGL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RIGL revenue history

Current Revenue
$157.5M
Current Earnings
$3.9M
Current Profit Margin
2.5%

Be the first to know when RIGL announces revenue.

RIGL Revenue History By Year

RIGL Yearly RevenueRIGL RevenueRIGL ChangeRIGL Revenue Growth
2023-12-31$116.88M-$3.36M-2.79%
2022-12-31$120.24M-$28.99M-19.43%
2021-12-31$149.24M$40.62M+37.39%
2020-12-31$108.62M$49.33M+83.21%
2019-12-31$59.29M$14.78M+33.20%
2018-12-31$44.51M$40.03M+892.62%
2017-12-31$4.48M-$15.90M-78.00%
2016-12-31$20.38M-$8.51M-29.46%
2015-12-31$28.90M$20.65M+250.24%
2014-12-31$8.25M$1.10M+15.38%
2013-12-31$7.15M$4.90M+217.78%
2012-12-31$2.25M-$2.50M-52.63%
2011-12-31$4.75M-$120.25M-96.20%
2010-12-31$125.00M$124.25M+16,566.67%
2009-12-31$750.00kN/AN/A
2008-12-31$0.00-$12.60M-100.00%
2007-12-31$12.60M-$20.87M-62.36%
2006-12-31$33.47M$16.95M+102.55%
2005-12-31$16.53M$11.79M+249.17%
2004-12-31$4.73M-$6.32M-57.19%
2003-12-31$11.06M-$4.73M-29.98%
2002-12-31$15.79M$485.00k+3.17%
2001-12-31$15.30M$2.09M+15.77%
2000-12-31$13.22M$4.23M+47.13%
1999-12-31$8.98M$8.96M+31,985.71%
1998-12-31$28.00kN/AN/A
1997-12-31$0.00N/AN/A

1 of 2

Rigel Pharmaceuticals Revenue FAQ

What was RIGL's revenue last quarter?

On Invalid Date, Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q3 2024 revenue of $55.31 million up 96.58% year over year. In the same quarter last year, Rigel Pharmaceuticals's revenue was $28.13 million.

What was Rigel Pharmaceuticals's revenue in 2023?

Rigel Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2023 was $116.88 million, a 2.79% decrease year over year.

How much does Rigel Pharmaceuticals make in a day?

Based on Rigel Pharmaceuticals annual revenue for the past five years, RIGL makes an average of $303,709.04 per day.

What was Rigel Pharmaceuticals's annual revenue growth in the past year?

As of Q1 2025, Rigel Pharmaceuticals's revenue has grown 18.97% year over year. This is 1,107.35 percentage points lower than the US Biotechnology industry revenue growth rate of 1,126.32%. Rigel Pharmaceuticals's revenue in the past year totaled $157.47 million.

How much does Rigel Pharmaceuticals make in a year?

Rigel Pharmaceuticals's revenue by year for the past five years is:
  • Rigel Pharmaceuticals's revenue for the twelve months ending Dec 31, 2023 was $116.88 million, a 2.79% decrease year over year.
  • Rigel Pharmaceuticals's annual revenue for Dec 31, 2022 was $120.24 million, a 19.43% decrease from 2021.
  • Rigel Pharmaceuticals's annual revenue for 2021 was $149.24 million, a 37.39% increase from 2020.
  • Rigel Pharmaceuticals's annual revenue for 2020 was $108.62 million, a 83.21% increase from 2019.
  • Rigel Pharmaceuticals's annual revenue for 2019 was $59.29 million, a 33.2% increase from 2018.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.